Dupuytren’s contracture| Volume 32, ISSUE 6, P767-774, July 2007

Efficacy and Safety of Injectable Mixed Collagenase Subtypes in the Treatment of Dupuytren’s Contracture


      To further evaluate the efficacy and safety of an injectable mixed subtype collagenase for the treatment of Dupuytren’s contracture (DC).


      Patients with flexion deformities of the metacarpophalangeal (MCP) and/or the proximal interphalangeal (PIP) joints of 20° or greater were randomized in a double-blind, placebo-controlled trial. Patients completing this phase could enter an open-label extension phase. The primary efficacy variable was clinical success: contracture correction to within 5° of normal (normal, 0°). Additional efficacy variables included the time and number of injections required to achieve success in the primary joint. Recurrence of contracture to 20° or greater in successfully treated joints and adverse events (AEs) were recorded.


      Thirty-three of 35 patients (mean ± SD, 61 ± 9 y) entering the double-blind phase completed the study; 19 of them entered the open-label extension. In the double-blind phase, clinical success of the primary joint was achieved in 16 of 23 patients receiving 1 injection and in 21 of 23 patients receiving 3 injections. No placebo-treated patients achieved joint correction. In the open-label extension, 17 of 19 patients achieved clinical success in at least 1 joint. The mean number of injections for clinical success in the double-blind and extension phases was 1.5 and 1.4, respectively; the time to clinical success ranged between 1 and 29 days. Overall, of 62 joints (31 MCP, 31 PIP) treated in 35 patients, 54 joints achieved clinical success. Over the 24-month follow-up period after the last injection, 5 joints had a recurrence. The most frequent treatment-related AEs were local reactions to injections. AEs were mild and resolved over several weeks. There were no serious treatment-related AEs.


      The collagenase injections safely and effectively corrected MCP and PIP contractures in patients with 1 or more DC-affected joints. Recurrence rates after treatment appear to be low. Data suggest that this collagenase appears to be a viable nonsurgical treatment option for DC.

      Type of study/level of evidence

      Therapeutic I.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hand Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gudmundsson K.
        Eighteen years follow-up study of the clinical manifestations and progression of Dupuytren’s disease.
        Scand J Rheumatol. 2001; 30: 31-34
        • Reilly R.
        A retrospective review of the management of Dupuytren’s nodules.
        J Hand Surg. 2005; 30A: 1014-1018
        • Townley W.A.
        • Baker R.
        • Sheppard N.
        • Grobbelaar A.O.
        Dupuytren’s contracture unfolded.
        BMJ. 2006; 332: 397-400
        • Ross D.C.
        Epidemiology of Dupuytren’s disease.
        Hand Clin. 1999; 15: 53-62
        • Early P.
        Population studies in Dupuytren’s contracture.
        J Bone Joint Surg. 1962; 44B: 602-613
        • Saboeiro A.P.
        • Porkorny J.J.
        • Shehadi S.I.
        • Virgo K.S.
        • Johnson F.E.
        Racial distribution of Dupuytren’s disease in Department of Veterans Affairs patients.
        Plast Reconstr Surg. 2000; 106: 71-75
        • Mikkelsen O.A.
        Dupuytren’s disease—a study of the pattern of distribution and stage of contracture in the hand.
        Hand. 1976; 8: 265-271
        • Rayan G.M.
        Clinical presentation and types of Dupuytren’s disease.
        Hand Clin. 1999; 15: 87-96
        • Gudmundsson K.G.
        • Arngrimsson R.
        • Sigfusson N.
        • Bjornsson A.
        • Jonsson T.
        Epidemiology of Dupuytren’s disease: clinical, serological, and social assessment. The Reykjavik Study.
        J Clin Epidemiol. 2000; 53: 291-296
        • van Rijssen A.L.
        • Werker P.M.
        Percutaneous needle fasciotomy in Dupuytren’s disease.
        J Hand Surg. 2006; 31B: 498-501
        • Makela E.A.
        • Jaroma H.
        • Harju A.
        • Anttila S.
        • Vainio J.
        Dupuytren’s contracture: the long-term results after day surgery.
        J Hand Surg. 1991; 16B: 272-274
        • Tonkin M.A.
        • Burke F.D.
        • Varian J.P.
        The proximal interphalangeal joint in Dupuytren’s disease.
        J Hand Surg. 1985; 10B: 358-364
        • Rodrigo J.J.
        • Niebauer J.J.
        • Brown R.L.
        • Doyle J.R.
        Treatment of Dupuytren’s contracture.
        J Bone Joint Surg. 1976; 58A: 380-387
        • McFarlane R.
        • Botz J.
        • Cheung H.
        Epidemiology of surgical patients.
        in: McFarlane R. McGrouther D. Flint M. Dupuytren’s disease. Churchill Livingstone, Edinburgh1990: 201-238
        • Bulstrode N.W.
        • Jemec B.
        • Smith P.J.
        The complications of Dupuytren’s contracture surgery.
        J Hand Surg. 2005; 30A: 1021-1025
        • Hurst L.C.
        • Badalamente M.A.
        Nonoperative treatment of Dupuytren’s disease.
        Hand Clin. 1999; 15: 97-107
        • Badalamente M.A.
        • Hurst L.C.
        Enzyme injection as nonsurgical treatment of Dupuytren’s disease.
        J Hand Surg. 2000; 25A: 629-636
        • Badalamente M.A.
        • Hurst L.C.
        • Hentz V.R.
        Collagen as a clinical target: nonoperative treatment of Dupuytren’s disease.
        J Hand Surg. 2002; 27A: 788-798
        • Tubiana R.
        • Leclercq C.
        • Hurst L.
        • Badalamente M.
        • Mackin E.
        Dupuytren’s disease. Martin Dunitz Ltd, London2000: 321
        • Au-Yong I.T.
        • Wildin C.J.
        • Dias J.J.
        • Page R.E.
        A review of common practice in Dupuytren surgery.
        Tech Hand Upper Extrem Surg. 2005; 9: 178-187